By Colin Kellaher 



  Bristol-Myers Squibb Co. on Tuesday said a pivotal Phase 3 study evaluating Zeposia as an induction and maintenance therapy for adults with moderate to severe ulcerative colitis met both primary endpoints. 


  The New York biopharmaceutical company said Zeposia showed highly statistically significant results for induction of clinical remission at 10 weeks and in maintenance at 52 weeks in patients with the chronic inflammatory bowel disease. 


  Bristol-Myers said the study also met key secondary endpoints of clinical response and endoscopic improvement in induction at 10 weeks and in maintenance at 52 weeks. 


  The company said the safety profile of Zeposia in the study was consistent with previous trials, adding that it plans to discuss the study results with health authorities. 


  Bristol-Myers, which in March received U.S. Food and Drug Administration for Zeposia for adults with relapsing forms of multiple sclerosis, is developing the drug for additional immune-inflammatory indications, including ulcerative colitis and Crohn's disease. 


  Write to Colin Kellaher at colin.kellaher@wsj.com